|
 |
SomavertThis page contains recent news articles, when available, and an overview of Somavert but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Somavert (when available) Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly. For treatment of acromegaly Mechanism Of Action: Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels. News Articles on Pegvisomant Pfizer's R&D: Spending vs. Productivity - Dec 10, 2009 His list of Pfizer NMEs since 2000 is Geodon (ziprasidone, 2001), Vfend (voriconazole, 2002), Relpax (eletriptan, 2002), Somavert (pegvisomant, 2003, ... Seeking Alpha (blog) Pfizer spending on R&D falls 11 percent - Dec 23, 2009 In fact, Pfizer has brought only nine medicines to market since 2000, according to Munos: Geodon, Vfend, Relpax, Somavert, Lyrica, Sutent, Chantix, ... Trading Markets (press release) Acromegaly - Symptoms, Diagnosis, Treatment of Acromegaly - NY Times … - Mar 18, 2008 Pegvisomant (Somavert) directly blocks the effects of growth hormone, and has been shown to improve symptoms of acromegaly. ... New York Times Pfizer's Somavert Available for Treatment of Acromegaly - Jan 24, 2006 MONTREAL, CANADA -- January 24, 2006 -- Health Canada has approved Somavert (pegvisomant for injection) for the treatment of patients with acromegaly who ... DG News Health Canada Issues Somavert Warning - Jun 11, 2008 Canadian regulatory authorities have warned that Somavert, a drug used to treat a life-threatening hormonal disorder, has been linked to liver problems when ... Newsinferno.com Acromegaly.(Adult Health Advisor 2007)(Disease/Disorder overview) - May 31, 2007 Medicines used to control or block growth hormone are octreotide (Sandostatin), cabergoline (Dostinex), bromocriptine (Parlodel), and pegvisomant (Somavert) ... $4.95 - Clinical Reference Systems - ECNext Federal Register 2007 - 72 FR 29172 Determination of Regulatory … - May 24, 2007 FDA recently approved for marketing the human drug product SOMAVERT (pegvisomant). SOMAVERT is indicated for the treatment of acromegaly in patients who ... Pay-Per-View - Federal Register 2007 - Loislaw SOMAVERT® (pegvisomant) DE PFIZER, PRIMER ANTAGONISTA … - May 23, 2005 SOMAVERT® (Pegvisomant) es el primero de una nueva clase de agentes farmacológicos conocidos como antagonistas del receptor de GH. ... acceso.com SOMAVERT® (Pegvisomant) ABRE UN NUEVO HORIZONTE EN EL … - Apr 13, 2005 ...- El Profesor John Kopchik, descubridor del fármaco, expuso en Madrid los beneficios de la terapia durante el VIII Simposium de Actualización en Patología ... acceso.com Engineering biopharmaceuticals: an overall increasing proportion of … - Nov 1, 2007 Somavert is indicated for the treatment of acromegaly, a rare endocrine ... Somavert acts as a hGH antagonist, reducing the effects of endogenous hGH while ... Free with registration - Biopharm International - AccessMyLibrary.com Le altre lettere - Jun 20, 2005 «Soffro di acromegalia, una patologia rara curabile con il Somavert, ... Il Somavert è in fascia H e può essere distribuito soltanto dal Centro ospedaliero ... Donna Moderna Press Release: GlaxoSmithKline's Topical Antibacterial Retapamulin … - Feb 14, 2006 Pharmacia Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved SOMAVERT(R) (pegvisomant for injection ... some forms of ... Pay-Per-View - PR Newswire - HighBeam Research 13 new drugs added to Japan's NHI list.(Central Social Insurance... - Mar 19, 2007 Pfizer's Somavert (pegvisomant), a treatment for acromegaly, was awarded NHI reimbursement prices of 12872 yen, 16318 yen and 19309 yen for, respectively, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Universities That Turn Research Into Revenue - Sep 12, 2008 Ohio University came in fourth (ROI: 13%), thanks to research on Somavert, a drug marketed by Pfizer (nyse: PFE - news - people ) to counteract the effect ... Forbes Nektar Crushed Under Pfizer's Boot (NKTR, PFE) - Oct 18, 2007 PEGASY for Hepatitis-C, Somavert for Acromegaly, PEG-INTRON for Hepatitis-C, Macugen for age-related macular degeneration, Cimzia for Crohn's disease, ... MarketWatch Inventions starting to pay off in a bigger way at OSU - Dec 21, 2007 The largest portion is for the drug Somavert, made by Pfizer Inc., which stops the action of human growth hormone to control acromegaly, a rare condition in ... Bizjournals.com FDA Panel Votes In Favor Of Nektar's Inhaled Insulin - Sep 12, 2005 They include Neulasta (Amgen Inc.) for infection caused by chemotherapy, Somavert (Pfizer Inc.) for acromegaly and Pegasys (F. Hoffmann-La Roche Ltd.) for ... BioWorld Online - BioWorld Online Manhattan Pharmaceuticals Names Alan Harris Chief Medical Officer - Feb 1, 2006 ...the growth hormone antagonist Somavert(r), and the leading international medical outcomes database containing information about growth hormone treatment ... primezone.com Treatments and drugs - Aug 2, 2008 The medication pegvisomant (Somavert), a growth hormone antagonist, acts to block the effect of GH on body tissues. Pegvisomant may be particularly helpful ... MayoClinic.com Urch Publishes Report on Orphan Drugs in Europe - Jan 5, 2005 The report contains detailed analysis of major orphan drugs Aldurazyme, Busilvex, Carbaglu, Fabrazyme, Glivec, Litak, PhotoBarr, Onsenal, Replagal, Somavert ... prweb.com Acromegaly.(Adult Health Advisor 2006)(Disease/Disorder overview) - Nov 1, 2006 Medicines used to control or block growth hormone are octreotide (Sandostatin), cabergoline (Dostinex), bromocriptine (Parlodel), and pegvisomant (Somavert) ... $4.95 - Clinical Reference Systems - ECNext Contract Manufacturing Fills Industry Niche - Oct 1, 2005 Diosynth Biotechnology manufactures commercial products such as Pfizer's Somavert, Organon's recombinant FSH Puregon, and Protein Design Labs' Retavase, ... Genetic Engineering News - Genetic Engineering News (press release) Pfizer moves to keep market share in Japan. - Mar 24, 2008 Mr Iwasaki said that Pfizer Japan gained manufacturing approvals for Celecox (celecoxib) in the treatment of arthritis and Somavert (pegvisomant) for ... $9.94 - Pharma Marketletter - Alacra Store Press Release: FDA approves Prograf to prevent rejection of heart … - Mar 31, 2006 Preminent Prograf Radicut Relenza Remicade Renivace Revatio Risperdal Somavert Sutent Takepron Taxol Topotecin Tracleer Valtrex Vesicare Viagra ... ... Pay-Per-View - M2 Presswire - HighBeam Research Orphans join European pharma family - Jul 5, 2005 Pharmacia-Pfizer's Somavert, Pierre Fabre's Busilvex, Axcan's PhotoBarr, Lipomed's Litak and Orphan Europe's Pedea are the only orphan drugs to date to ... Pharmafocus Press Release: Bellwether Report.com is Following Nektar Therapeutics.... - Sep 19, 2006 ...anti-infective Neulasta, Bristol-Myers Squibb's Definity ultrasound contrast agent, and Pfizer's human growth hormone receptor antagonist Somavert. ... Pay-Per-View - M2 Presswire - HighBeam Research Acromegaly.(care and treatment) - May 24, 2006 Medicines used to control or block growth hormone are octreotide (Sandostatin), cabergoline (Dostinex), bromocriptine (Parlodel), and pegvisomant (Somavert) ... $4.95 - Clinical Reference Systems - ECNext BE Etats-Unis 138 >> 17/10/2008 - Oct 17, 2008 ...par un contrat de licence avec "General Electric" et l'université de l'Ohio, quatrième au classement détient 90% de ses royalties grâce à Somavert, ... bulletins-electroniques.com Gene to screen: the coming of RNAi gene silencing, modified human … - Jan 3, 2005 ...the launch of the highly modified and more selective growth hormone receptor antagonist Somavert by Pfizer indicates that it will soon become the norm. ... $4.95 - Chemistry and Industry - ECNext Malattie endocrino-metaboliche: l'acromegalia caratterizzata da … - Apr 29, 2008 Per i pazienti in cui la terapia con analoghi della Somatostatina risulti inefficace, può trovare impiego Pegvisomant ( Somavert ), un antagonista del ... XagenaSalute Med särskild blick för särläkemedel - Sep 27, 2006 Flera enzymersättningspreparat, Glivec mot ovanliga cancerformer och Somavert mot akromegali har exempelvis betytt mycket. ... Läkemedelsvärlden Universitatile transforma cercetarea in bani - Sep 18, 2008 Pe locul patru se afla Universitatea din Ohio, cu un randament de 13%, multumita lui Somavert, un medicament scos pe piata de Pfizer, care contracareaza ... Bloombiz … Langzeit-Anwendungsbeobachtung: Aktuelle Ergebnisse belegen die … - Sep 28, 2005 Der GH-Rezeptorantagonist Pegvisomant (Somavert®) stellt in dieser Hinsicht einen großen Fortschritt in der Therapie der Akromegalie dar. ... journalmed.de Brand Names/Synonyms: Somavert is also known by the following brand names and/or synonymsSomatotropin precursor;Growth hormone;GH;GH-N;Pituitary growth hormone;Growth hormone 1; Somavert (Pfizer Inc) Drug Category: Somavert is categorized under the following by the FDA: Anabolic Agents; Hormone replacement Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: PEGylated human growth hormone |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |